Long‐term results of a randomized, double‐blind, and placebo‐controlled phase III trial: Endostar (rh‐endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non‐small cell lung cancer
Authors:
Open Access
- 3 May 2013
- journal article
- research article
- Published by Wiley in Thoracic Cancer
- Vol. 4 (4) , 440-448
Abstract
Background: : Phase II‐III trials in patients with untreated and previously treated locally advanced or non‐small cell lung cancer (NSCLC) suggested that Endostar was able to enhance the effect of platinum‐based chemotherapy (NP regimen) with tolerable adverse effects.Methods: Four hundred and eighty six patients were randomized into two arms: study arm A: NP plus Endostar (n = 322; vinorelbine, cisplatin, Endostar), and study arm B: NP plus placebo (n = 164; vinorelbine, cisplatin, 0.9% sodium chloride). Patients were treated every third week for two to six cycles.Results: : Overall response rates were 35.4% in arm A and 19.5% in arm B (P = 0.0003). The median time to progression was 6.3 months for arm A and 3.6 months for B, respectively (P < 0.001). The clinical benefit rates were 73.3% in arm A and 64.0% in arm B (P = 0.035). Grade 3/4 neutropenia, anemia, and nausea/vomiting were 28.5%, 3.4%, and 8.0%, respectively, in Arm A compared with 28.2%, 3.0%, and 6.6%, respectively, in Arm B (P > 0.05). There were two treatment related deaths in arm A and one in arm B (P > 0.05). The median overall survival was longer in arm A than in arm B (P < 0.0001).Conclusion: : Long‐term follow‐up revealed that the addition of Endostar to an NP regimen can result in a significant clinical and survival benefit in advanced NSCLC patients, compared with NP alone.Keywords
This publication has 33 references indexed in Scilit:
- Endostar, a modified recombinant human endostatin, exhibits synergistic effects with dexamethasone on angiogenesis and hepatoma growthCancer Letters, 2011
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialThe Lancet, 2008
- Endostatin finds a new partner: nucleolinBlood, 2007
- Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cellsBiochemical and Biophysical Research Communications, 2007
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Angiogenic balance in human melanoma: Expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenograftsin vivoInternational Journal of Cancer, 2000
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI: Journal of the National Cancer Institute, 1990
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971